Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test
oleh: Shun Ishido, Nobuharu Tamaki, Kento Inada, Jun Itakura, Yuka Takahashi, Naoki Uchihara, Keito Suzuki, Yuki Tanaka, Haruka Miyamoto, Michiko Yamada, Hiroaki Matsumoto, Tsubasa Nobusawa, Taisei Keitoku, Kenta Takaura, Shohei Tanaka, Chiaki Maeyashiki, Yutaka Yasui, Kaoru Tsuchiya, Hiroyuki Nakanishi, Masayuki Kurosaki, Namiki Izumi
| Format: | Article |
|---|---|
| Diterbitkan: | Wiley 2023-07-01 |
Deskripsi
Key Clinical Message The liquid CGP was useful for detecting FGFR2 fusion and the patient experienced typical side effects (nail disorders, hyperphosphatemia, and taste disorders) of pemigatinib that required treatment.